2nd Quarter - Report

COVINGTON & BURLING LLP for CELGENE CORPORATION

Period 2nd Quarter 2018 Filed Jul 19, 2018 Signed by William Wichterman

Official filing
Firm
COVINGTON & BURLING LLP
Client
CELGENE CORPORATION
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Expressing support for changes to the CREATES Act (H.R. 2212, S. 974) and Fair Access for Safe and Timely (FAST) Generics Act (H.R. 2051). Analyzing the impact of SOUND Disposal and Packaging Act (HR 5687), the Opioid Crisis Response Act of 2018 (S. 2680), and the Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now Act" (the "SCREEN Act"), H.R. 5228.

LobbyistCovered position, as disclosed
KRISTA CARVER —
CHRISTINA KUHN —
GABRIEL NEVILLE —
WILLIAM WICHTERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5228 (115th), H.R. 2212 (115th), S. 2680 (115th), H.R. 5687 (115th), S. 974 (115th), H.R. 2051 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.